|Place of Origin:||China|
|Model Number:||250mg/5ml; 400mg/5ml|
|Minimum Order Quantity:||50000 boxes|
|Packaging Details:||one bottle/box|
|Supply Ability:||50, 000 bottles per day|
|Product:||Amoxicillin For Oral Suspension||Specification:||250mg/5ml; 400mg/5ml|
|Standard:||BP, USP||Packing:||One Bottle/box|
Amoxicillin for Oral Suspension 250mg/5ml; 400mg/5ml , Oral Medications
Product : Amoxicillin for oral Suspension
Specification : 250mg/5ml; 400mg/5ml
Standard : BP, USP
Packing : one bottle/box
Each 5 mL of reconstituted suspension for oral administration contains 250 mg or 400 mg amoxicillin as the trihydrate.
Indications and usage:
Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) strains of the designated microorganisms in the conditions listed below:
Infections of the ear, nose, and throat – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.
Infections of the genitourinary tract– due to E. coli, P. mirabilis, or E. faecalis.
Infections of the skin and skin structure– due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli.
Infections of the lower respiratory tract– due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.
Gonorrhea, acute uncomplicated (ano-genital and urethral infections)– due to N. gonorrhoeae (males and females).
H. pylori eradication to reduce the risk of duodenal ulcer recurrence
Amoxicillin for oral suspension, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.)
Amoxicillin for oral suspension, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.)
To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin for oral suspension and other antibacterial drugs, amoxicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Indicated surgical procedures should be performed.